On Friday, Mineralys Therapeutics reached an important technical milestone, with its Relative Strength (RS) Rating entering into the 80-plus percentile with an improvement to 82, a rise from 75 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
History reveals that the best-performing stocks often have an RS Rating of above 80 in the early stages of their moves.
Mineralys Therapeutics is trying to complete a cup with handle with a 16.90 buy point. See if the stock can break out in volume at least 40% above average.
The company reported 0% earnings growth in the latest quarterly report, while sales growth came in at 0%.
The company holds the No. 231 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
